Trial reportAntimicrobial agents and chemotherapy2009
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Trial report in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06156566 (European Randomised Clinical Trial on mPOX Infection), which is not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Randomised Clinical Trial on mPOX Infection
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Therapeutics for treating mpox in humans.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Oral Tecovirimat for the Treatment of Smallpox.The New England journal of medicine · 2018Trial
- Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.Antimicrobial agents and chemotherapy · 2012Trial
- Mpox animal models: a comprehensive evaluation of susceptible species for pathogenesis studies and drug discovery.Emerging microbes & infections · 2026Review
- Discovery of the nucleoside analogue FMAU as a broad-spectrum anti-orthopoxvirus inhibitor in vitro and in vivo using a structure-guided hit expansion strategy.Emerging microbes & infections · 2026Article
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Tecovirimat for the Treatment of Mpox.The New England journal of medicine · 2026Article
- Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.The Journal of infectious diseases · 2026Article
- Mpox: disease manifestations and therapeutic development.Journal of virology · 2025Review
- Monkeypox: Prevention Strategies and Challenges: Updated Review.Health science reports · 2025Article
- The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era.New microbes and new infections · 2024Review
- Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses.Microbiology spectrum · 2024Article
- Cardiac glycosides inhibit early and late vaccinia virus protein expression.The Journal of general virology · 2024Article
- Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methods.PLoS pathogens · 2024Article
- Clinical considerations on monkeypox antiviral medications: An overview.Pharmacology research & perspectives · 2024Review
- From Outbreaks to Artificial Intelligence: A Comprehensive Review of Monkeypox Virus Epidemiology, Diagnosis, Treatment, Vaccination, and Deep Learning Applications.Journal of tropical medicine · 2024Review
- Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.Emerging infectious diseases · 2023Article
- Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.PLoS biology · 2023Article
- Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.Open forum infectious diseases · 2023Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutics for the treatment of pathogenic orthopoxvirus infections are being sought. In the absence of patients with disease, animal models of orthopoxvirus disease are essential for evaluation of the efficacies of antiviral drugs and establishment of the appropriate dose and duration of human therapy. Infection of nonhuman primates (NHP) by the intravenous injection of monkeypox virus has been used to evaluate a promising therapeutic drug candidate, ST-246. ST-246 administered at 3 days postinfection (which corresponds to the secondary viremia stage of disease) at four different doses (from 100 mg/kg of body weight down to 3 mg/kg) once a day for 14 days was able to offer NHP 100% protection from a lethal infection with monkeypox virus and reduce the viral load and lesion formation. In NHP, the administration of ST-246 at a dose of 10 mg/kg/day for 14 days resulted in levels of blood exposure comparable to the levels attained in humans administered 400 mg in the fed state. These results suggest that administration of an oral dosage of 400 mg once daily for 14 days will be effective for the prevention or treatment of smallpox or monkeypox infections in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.